Introduction
iron beads [4] , plasmid [5] and liposomes [6] . HIV [7, 8] .
transactivator of transcription (TAT) peptide is one of the CPPs that has been broadly investigated. TAT has been shown to mediate delivery of biological agents both in vitro and in vivo. Its ability to translocate into live cells and cross biological barriers (e.g. blood-brain barrier) that makes it a potential novel vehicle for clinical drug delivery
In this study, we investigated the potential of TAT to deliver human acidic fibroblast growth factor (aFGF19-154) from the eyeball surface to the retina in rats. aFGF (also known as FGF-1) is one of the most powerful and broad-spectrum mitogens in the FGF family. aFGF regulates the development and morphogenesis of the ectoderm-and mesoderm-derived cells, wound healing, haematopoiesis, angiogenesis, inflammatory processes as well as tumorigenesis [9] [10] [11] [12] [13] [14] [15] [16] . aFGF has also been reported to mediate potent protection against ischemia-reperfusion (IR) injury in the brain and heart tissues [17, 18] . Our results showed that TATaFGF-His, but not aFGF-His, can efficiently penetrate the ocular barriers and mediate strong protection against retinal IR injury. 
Materials and methods

Animals
Ischemia-reperfusion model
Rats were anaesthetized by intraperitoneal injection of 10% chloral hydrate (3 ml/kg [19] . Retinal ischemia was confirmed by the loss of the red reflex in retinal arteries and the paleness of the bulbar conjunctiva using an ophthalmoscope. After an ischemic period of 60 min., the needle was removed from the anterior chamber, and the reperfusion was confirmed by seeing the recovery of the red reflex in retina arteries by ophthalmoscopy.
Preparation and administration of fusion protein aFGF-His and TAT-aFGF-His
Fusion protein aFGF-His and TAT-aFGF-His were generated in our laboratory, as previously described [20] 
Topical administration of TAT-aFGF-His eye drops protects against retinal ischemia-reperfusion injury
It has been reported that injection of aFGF through jugular vein reduces retinal IR injury in rats [19] . To determine whether TAT-aFGF (Fig. 1B) . However, significant protection against IR injury was seen in the TAT-aFGF-His treated-group. Retinas from TAT-aFGF-His treated eyes showed markedly less severe pathological changes, including better maintained histological structure (Fig. 2B ) and a lower reduction in RGC numbers (Fig. 3) , compared to those treated with PBS or aFGF-His. Furthermore, TUNEL staining revealed that TAT-aFGF-His treatment also reduced IR-induced RGC apoptosis. As shown in Table 1 and [21] . Thus, suppression of the b-wave of the ERG has been taken as an electrophysiological indicator for reduced retinal blood flow in human beings [22] and in experimental animals [23] . ERG b-wave amplitudes in the TAT-aFGF-His-treated group at days 3 and 7 were significantly higher than those in BPS-and aFGF-His-treated groups (Fig. 5 and Table 2 ). Table 1 [24] [25] [26] . Several have reported that cargos anchored with TAT can cross the blood-brain barrier [7, 20, 27] . [28] [29] [30] [31] . However, in agreement with the inability of aFGF to penetrate the ocular barriers (Fig. 1B) [33, 34] , the existence of cell-specific mechanisms for cellular entry of TAT peptides has been suggested by the observation that TAT peptides were poorly or non-permeable in well-differentiated epithelial cells [35] . The selective uptake of TAT conjugates by retinal cells was also reported, in which TAT conjugates were predominately uptaken by RGCs and by a subset of inner nuclear layer cells [36, 37] . In our studies, the uptake of TAT-aFGF-His proteins was also detected mainly in RGCs. Because RGC death following ischemic insult is the major cause of a number of vision-threatening diseases, selective delivery of aFGF to RGCs may have the potential to improve the therapeutic outcome.
Fig. 3 TAT-aFGF-His, but no aFGF-His protects against IR-induced reduction in ganglion cells in the GCL. Rats were treated with PBS (ٗ), 2 g aFGF-His () or TAT-aFGF-His () on days 0, 2 and 4 after retinal IR. Eyes were harvested at days 1, 3 and 7 after IR, and retina samples were prepared and stained with haematoxylin and eosin (five rats per group were analysed at each time-point). The number of ganglion cells in the GCL was counted in five vision fields of 100-m length across the retina. Data are presented as the ratio (mean Ϯ S.D.s) of the experimental eyes to the sham-operated control eyes. *P Ͻ 0.05, **P Ͻ 0.01 fusion proteins remain biologically functional, we assessed the therapeutic effect of TAT-aFGF-His in a rat retinal IR injury model. Compared to sham-operated eyes (Fig. 2A), IR resulted in severe injury in the PBS control group (Figs 2 and 3): on day 1, the retina appeared dropsical (especially the inner plexiform layer), and showed reduced RGCs in the GCL, interrupted cellular distribution in the INL, and an increased number of cells with pyknotic nuclei in the INL; on day 3, the condition of oedema was subsidized, but the number of RGCs kept decreasing; on day 7, most RGCs in the GCL exhibited pyknotic nuclei. Similar pathological changes were seen in the retina following IR in the aFGF-Histreated group (Figs 2B and 3), which is consistent with the inability of aFGF-His to penetrate through the ocular barriers to the retina
Fig. 4, the numbers of apoptotic cells in the GCL were significantly less in TAT-aFGF-His-treated group than those in PBS-and aFGF-His treated groups at days 3 and 7 after IR. Retinal function was further determined by ERGs. ERG measurements reflect the physiological condition of the whole retina. At day 1 after IR, a significant decrease (P Ͻ 0.05) in the amplitudes of ERG a-wave, b-wave and Ops was seen in all groups (Fig. 5 and Table 2). However, TAT-aFGF-His-treated group showed accelerated recovery compared to those treated with PBS or aFGF-His. Both PBS-and aFGF-His-treated groups showed continued decreases in ERG a-wave, b-wave and Ops between day 1 and day 3, whereas all these ERG measurements began increasing 3 days after IR. It has been reported that acute retinal ischemia results in a predominant loss of the b-wave with relative preservation of the a-wave
In the present study, we proved that TAT-PTD (TAT49-57) provides a potential vehicle for drug delivery to retina. We observed that TAT-aFGF-His, but not aFGF-His, can be detected in the retina after topical administration to the ocular surface. TAT-aFGF-His
